Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Group name EquipeMY
Item Type Journal Article
Title Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients
Creator Mbatchi et al.
Author Litaty Céphanoée Mbatchi
Author Jacques Robert
Author Marc Ychou
Author Jean-Christophe Boyer
Author Maguy Del Rio
Author Matthieu Gassiot
Author Fabienne Thomas
Author Nicole Tubiana
Author Alexandre Evrard
Abstract BACKGROUND AND OBJECTIVES: Nuclear receptors PXR (pregnane X receptor, NR1I2) and CAR (constitutive androstane receptor, NR1I3) are key regulators of irinotecan metabolism, and ligand-dependent modulation of their activity leads to significant drug-drug interactions. Because genetic polymorphisms can also affect the activity of these xenobiotic-sensing receptors, we hypothesized that they could contribute to the interpatient variability of irinotecan pharmacokinetics and to the toxicity of irinotecan-based regimens. PATIENTS AND METHODS: In a cohort of 109 metastatic colorectal cancer patients treated with irinotecan (180 mg/m(2)) in combination with other drugs, associations were assessed between 21 selected single nucleotide polymorphisms of NR1I2 or NR1I3 and pharmacokinetic parameters or toxicity of irinotecan and its metabolites. RESULTS: After adjustment of the tests by the UGT1A1*28 genotype and correction for multiple testing, the A allele of NR1I2-rs10934498 was associated with a decreased exposition and an increased degradation of SN-38, the active metabolite (p = 0.009 and p = 0.017, respectively). The risk of hematological toxicity was associated with NR1I2-rs10934498 and NR1I2-rs2472677 (p = 0.009 and p = 0.003, respectively). CONCLUSION: Our results reveal for the first time the involvement of NR1I2 in the pharmacogenetics of irinotecan and suggest that it may help to predict the toxicity of low-dose irinotecan.
Publication Clinical Pharmacokinetics
Volume 55
Issue 9
Pages 1145-1157
Date 09 2016
Journal Abbr Clin Pharmacokinet
Language eng
DOI 10.1007/s40262-016-0392-5
ISSN 1179-1926
Library Catalog PubMed
Extra PMID: 27116457
Tags Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic, Camptothecin, Cohort Studies, Colorectal Neoplasms, Drug Interactions, Female, France, Genetic Markers, Humans, Male, Middle Aged, Neoplasm Metastasis, original, Polymorphism, Single Nucleotide, Predictive Value of Tests, Receptors, Cytoplasmic and Nuclear, Receptors, Steroid, Xenobiotics
Date Added 2018/11/13 - 17:25:35
Date Modified 2019/05/21 - 14:44:22


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés